Simvastatin reverses cardiomyocyte hypertrophy via the upregulation of phosphatase and tensin homolog expression
- Authors:
- Yong‑Qing Chen
- Lian‑You Zhao
- Wei‑Ze Zhang
- Tao Li
View Affiliations
Affiliations: Department of Cardiology, General Hospital of Lanzhou Military Area Command, Lanzhou, Gansu 730050, P.R. China, Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
- Published online on: June 5, 2015 https://doi.org/10.3892/etm.2015.2550
-
Pages:
797-803
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the present study was to investigate the effects of simvastatin on the protein kinase B (PKB) signaling pathway and the expression of phosphatase and tensin homolog (PTEN). The effects of simvastatin were analyzed by administering the drug orally to male spontaneously hypertensive rats (SHRs) at a dose of 10 mg/kg/day, while the control animals received an equal volume of saline. The systolic pressure (mmHg) of the rat tail artery was measured prior to the initiation of the experiment, and once a week until the end of the experiment. At the end of the experiment, the animals were euthanized and the hearts were removed. The left ventricular and interventricular septum were weighed, after which the left ventricular mass/body mass ratio was calculated. In addition, cardiomyocytes isolated from Sprague Dawley rats were cultured with 15% fetal bovine serum to induce hypertrophy, following which the cells were treated with different doses of simvastatin. The in vitro effects were assessed by measuring the surface area of the cardiomyocytes, while the rate of protein synthesis was measured using a 3H‑leucine incorporation assay and western blot analyses. Simvastatin was demonstrated to inhibit cardiomyocyte hypertrophy in the in vivo and in vitro experiments. Notably, simvastatin increased PTEN expression and inhibited PKB expression in the SHR model, as well as in the cardiomyocytes in culture. In addition, the use of PTEN antisense oligodeoxynucleotides was revealed to inhibit the effects of simvastatin on cardiomyocytes. Therefore, these results indicated that simvastatin was able to reverse cardiomyocyte hypertrophy in vivo and in vitro, possibly by increasing the expression of PTEN.
View References
|
1
|
Zheng H and Lu GM: Reduction of prohibitin
expression contributes to left ventricular hypertrophy via
enhancement of mitochondrial reactive oxygen species formation in
spontaneous hypertensive rats. Free Radic Res. 49:164–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koh KK, Sakuma I and Quon MJ: Differential
metabolic effects of distinct statins. Atherosclerosis. 215:1–8.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugden PH: Ras, Akt, and
mechanotransduction in the cardiac myocyte. Circ Res. 93:1179–1192.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez J and Sellers WR: PI3K/PTEN/AKT
pathway. A critical mediator of oncogenic signaling. Cancer Treat
Res. 115:145–167. 2003.PubMed/NCBI
|
|
6
|
Shiojima I and Walsh K: Regulation of
cardiac growth and coronary angiogenesis by the Akt/PKB signaling
pathway. Genes Dev. 20:3347–3365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Berlo JH, Maillet M and Molkentin JD:
Signaling effectors underlying pathologic growth and remodeling of
the heart. J Clin Invest. 123:37–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stuenaes JT, Bolling A, Ingvaldsen A, et
al: Beta-adrenoceptor stimulation potentiates insulin-stimulated
PKB phosphorylation in rat cardiomyocytes via cAMP and PKA. Br J
Pharmacol. 160:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maire CL, Ramkissoon S, Hayashi M, Haidar
S, Ramkissoon L, DiTomaso E and Ligon KL: Pten loss in Olig2
expressing neural progenitor cells and oligodendrocytes leads to
interneuron dysplasia and leukodystrophy. Stem Cells. 32:313–326.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crackower MA, Oudit GY, Kozieradzki I, et
al: Regulation of myocardial contractility and cell size by
distinct PI3K-PTEN signaling pathways. Cell. 110:737–749. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Cheng X, Liao YH, et al:
Simvastatin regulates myocardial cytokine expression and improves
ventricular remodeling in rats after acute myocardial infarction.
Cardiovasc Drugs Ther. 19:13–21. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simpson P, McGrath A and Savion S: Myocyte
hypertrophy in neonatal rat heart cultures and its regulation by
serum and by catecholamines. Circ Res. 51:787–801. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi YS, Dusting GJ, Stubbs S, et al:
Differentiation of human adipose-derived stem cells into beating
cardiomyocytes. J Cell Mol Med. 14:878–889. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clunn GF, Sever PS and Hughes AD: Calcium
channel regulation in vascular smooth muscle cells: Synergistic
effects of statins and calcium channel blockers. Int J Cardiol.
139:2–6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Q, Cui W, Zhang HL, Hu HJ, Zhang YN,
Liu DM and Liu J: Atorvastatin suppresses aldosterone-induced
neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2
in the genomic pathway. J Cardiovasc Pharmacol. 61:520–527. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santalucía T, Christmann M, Yacoub MH and
Brand NJ: Hypertrophic agonists induce the binding of c-Fos to an
AP-1 site in cardiac myocytes: Implications for the expression of
GLUT1. Cardiovasc Res. 59:639–648. 2003. View Article : Google Scholar : PubMed/NCBI
|
